Aptose Biosciences Inc. closes C$8M public offering
Date Closed
November 25, 2024
Lead Office
Québec City
Value
8.00 Million CAD
On November 25, 2024, Aptose Biosciences Inc. ("Aptose") closed its public offering for the purchase and sale of 40,000,000 common shares at a price of $0.20 per share and warrants to purchase up to 20,000,000 common shares with aggregate gross proceeds of C$8 million.
Aptose, headquartered in San Diego, California and Toronto, Ontario, Ontario, is a Canadian clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.
McCarthy Tétrault advised Aptose with a team led by Charles-Antoine Soulière that included Shariff Farhiyah, Asma Boudoukha, Annie Poirier-Simard and Yassine Khadir (Business).